Juniper Biologics Acquired Cell-Mediated Gene Therapy TG-C LD For Knee Osteoarthritis


Juniper Biologics has obtained the licensing rights for the development and commercialisation of Kolon Life Science’s cell-mediated gene therapy, TissueGene-C low dose (TG-C LD), to treat knee osteoarthritis. Juniper will develop and market TG-C LD in the Asia Pacific, the Middle East and Africa under the $600m licensing deal.

Article Summary

A non-surgical investigational therapy, TG-C LD is claimed to be the first in the world to potentially treat knee osteoarthritis, which is a common form of arthritis. It is administered as a single intra-articular injection. Furthermore, Kolon will extend support for the gene therapy development and supply. 

Preliminary findings from the trial showed that a single injection of TG-C in the knee joint offered lasting pain relief and improvement in mobility for possibly up to two years. TG-C’s licence holder in the US, Kolon TissueGene, has concluded a Phase II clinical trial in the country. Phase III trials enrolling 1,020 patients in the US are currently underway to validate the safety and efficacy of TG-C. 

Apart from establishing the statistically significant decline in pain and function improvements reported in the US Phase II trial, these trials are intended to demonstrate the delay of disease progression to obtain a Disease-Modifying Osteoarthritis Drug designation.

About Juniper Biologics

Juniper specialises in Researching, Developing & Commercialising novel therapies, with a clear focus on Oncology, Rare/Orphan Diseases and Gene Therapy.

 (Source: Juniper Biologics, 13th April 2022)


Leave A Comment

Leave a Reply

Your email address will not be published.